


# IMMUNOGEN

ImmunoGen, Inc.  
Investor Relations Department  
830 Winter Street  
Waltham, MA 02451  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#) 

## NASDAQ: IMGN

Last Trade:	6.10
Trade Time:	3:22 PM ET Aug 17, 2017
Change:	-0.02  (-0.327%)
Day Range	6.01 - 6.30
52-Week Range	1.51 - 8.04
Volume	1,510,312

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology.

ImmunoGen's lead product candidate, mirvetuximab soravtansine, is in a Phase 3 trial for FR $\alpha$ -positive platinum-resistant ovarian cancer, and is in Phase 1b/2 testing in combination regimens for earlier-stage disease. ImmunoGen's ADC technology is used in Roche's marketed product, Kadcyla<sup>®</sup>, in other clinical-stage ImmunoGen product candidates, and in programs in development by Amgen, Bayer, B... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

Aug 1, 2017

[ImmunoGen Announces Webcast of Presentation at the Canaccord Genuity Growth Conference](#)

Jul 28, 2017

[ImmunoGen Reports Recent Progress and Second Quarter 2017 Operating Results](#)

Jul 14, 2017

[ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2017 Financial Results](#)

Jun 26, 2017

[ImmunoGen Presents Data from Phase I Study of IMGN779 in Acute Myeloid Leukemia](#)

May 30, 2017

[ImmunoGen and Sanofi Amend License Agreements](#)

## Financials [\[ View all \]](#)

[Second Quarter Financial Results](#)

Aug 25, 2016

[Annual Report \(10-K\)](#)

Apr 28, 2017

[Proxy Statement \(DEF 14A\)](#)

Aug 4, 2017

[Quarterly Report \(10-Q\)](#)

May 5, 2017

[Quarterly Report \(10-Q\)](#)

Nov 4, 2016

[Quarterly Report \(10-Q\)](#)